Cargando…
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
Additional sex combs-like (ASXL) proteins are mammalian homologues of additional sex combs (Asx), a regulator of trithorax and polycomb function in Drosophila. While there has been great interest in ASXL1 due to its frequent mutation in leukemia, little is known about its paralog ASXL2, which is fre...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454368/ https://www.ncbi.nlm.nih.gov/pubmed/28516957 http://dx.doi.org/10.1038/ncomms15429 |
_version_ | 1783240818180489216 |
---|---|
author | Micol, Jean-Baptiste Pastore, Alessandro Inoue, Daichi Duployez, Nicolas Kim, Eunhee Lee, Stanley Chun-Wei Durham, Benjamin H. Chung, Young Rock Cho, Hana Zhang, Xiao Jing Yoshimi, Akihide Krivtsov, Andrei Koche, Richard Solary, Eric Sinha, Amit Preudhomme, Claude Abdel-Wahab, Omar |
author_facet | Micol, Jean-Baptiste Pastore, Alessandro Inoue, Daichi Duployez, Nicolas Kim, Eunhee Lee, Stanley Chun-Wei Durham, Benjamin H. Chung, Young Rock Cho, Hana Zhang, Xiao Jing Yoshimi, Akihide Krivtsov, Andrei Koche, Richard Solary, Eric Sinha, Amit Preudhomme, Claude Abdel-Wahab, Omar |
author_sort | Micol, Jean-Baptiste |
collection | PubMed |
description | Additional sex combs-like (ASXL) proteins are mammalian homologues of additional sex combs (Asx), a regulator of trithorax and polycomb function in Drosophila. While there has been great interest in ASXL1 due to its frequent mutation in leukemia, little is known about its paralog ASXL2, which is frequently mutated in acute myeloid leukemia patients bearing the RUNX1-RUNX1T1 (AML1-ETO) fusion. Here we report that ASXL2 is required for normal haematopoiesis with distinct, non-overlapping effects from ASXL1 and acts as a haploinsufficient tumour suppressor. While Asxl2 was required for normal haematopoietic stem cell self-renewal, Asxl2 loss promoted AML1-ETO leukemogenesis. Moreover, ASXL2 target genes strongly overlapped with those of RUNX1 and AML1-ETO and ASXL2 loss was associated with increased chromatin accessibility at putative enhancers of key leukemogenic loci. These data reveal that Asxl2 is a critical regulator of haematopoiesis and mediates transcriptional effects that promote leukemogenesis driven by AML1-ETO. |
format | Online Article Text |
id | pubmed-5454368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-54543682017-06-07 ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia Micol, Jean-Baptiste Pastore, Alessandro Inoue, Daichi Duployez, Nicolas Kim, Eunhee Lee, Stanley Chun-Wei Durham, Benjamin H. Chung, Young Rock Cho, Hana Zhang, Xiao Jing Yoshimi, Akihide Krivtsov, Andrei Koche, Richard Solary, Eric Sinha, Amit Preudhomme, Claude Abdel-Wahab, Omar Nat Commun Article Additional sex combs-like (ASXL) proteins are mammalian homologues of additional sex combs (Asx), a regulator of trithorax and polycomb function in Drosophila. While there has been great interest in ASXL1 due to its frequent mutation in leukemia, little is known about its paralog ASXL2, which is frequently mutated in acute myeloid leukemia patients bearing the RUNX1-RUNX1T1 (AML1-ETO) fusion. Here we report that ASXL2 is required for normal haematopoiesis with distinct, non-overlapping effects from ASXL1 and acts as a haploinsufficient tumour suppressor. While Asxl2 was required for normal haematopoietic stem cell self-renewal, Asxl2 loss promoted AML1-ETO leukemogenesis. Moreover, ASXL2 target genes strongly overlapped with those of RUNX1 and AML1-ETO and ASXL2 loss was associated with increased chromatin accessibility at putative enhancers of key leukemogenic loci. These data reveal that Asxl2 is a critical regulator of haematopoiesis and mediates transcriptional effects that promote leukemogenesis driven by AML1-ETO. Nature Publishing Group 2017-05-18 /pmc/articles/PMC5454368/ /pubmed/28516957 http://dx.doi.org/10.1038/ncomms15429 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Micol, Jean-Baptiste Pastore, Alessandro Inoue, Daichi Duployez, Nicolas Kim, Eunhee Lee, Stanley Chun-Wei Durham, Benjamin H. Chung, Young Rock Cho, Hana Zhang, Xiao Jing Yoshimi, Akihide Krivtsov, Andrei Koche, Richard Solary, Eric Sinha, Amit Preudhomme, Claude Abdel-Wahab, Omar ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia |
title | ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia |
title_full | ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia |
title_fullStr | ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia |
title_full_unstemmed | ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia |
title_short | ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia |
title_sort | asxl2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454368/ https://www.ncbi.nlm.nih.gov/pubmed/28516957 http://dx.doi.org/10.1038/ncomms15429 |
work_keys_str_mv | AT micoljeanbaptiste asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT pastorealessandro asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT inouedaichi asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT duployeznicolas asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT kimeunhee asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT leestanleychunwei asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT durhambenjaminh asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT chungyoungrock asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT chohana asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT zhangxiaojing asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT yoshimiakihide asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT krivtsovandrei asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT kocherichard asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT solaryeric asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT sinhaamit asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT preudhommeclaude asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia AT abdelwahabomar asxl2isessentialforhaematopoiesisandactsasahaploinsufficienttumoursuppressorinleukemia |